METTL1-catalyzed m7G tRNA modification selectively enhances translation of resistance-associated transcripts, attenuating responsiveness to lenvatinib—a first-line multikinase inhibitor for advanced HCC [185]. This evidence concerns the gene METTL1 and hepatocellular carcinoma.